Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

This study tests whether using two drugs — zanubrutinib (a BTK inhibitor) and lenalidomide (an immune-modulating drug) — as maintenance therapy after achieving remission can help prevent diffuse large B-cell lymphoma (DLBCL) from coming back. **You may be eligible if...** - You have been diagnosed with diffuse large B-cell lymphoma (DLBCL) - You have achieved complete remission after chemotherapy - You are 18 or older - Your blood counts meet the minimum thresholds (adequate neutrophils, platelets, and hemoglobin) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have an active, uncontrolled infection requiring systemic treatment - You have a serious unstable medical condition (severe heart, liver, kidney, or metabolic disease) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.